Gordon Gillerman

Gordon Gillerman, Director, Standards Coordination Office at the National Institute of Standards and Technology (NIST) and Department of Commerce Standards Executive, leads NIST’s work in standards coordination and the National Voluntary Laboratory Accreditation Program. Gordon supports extensive standards development and advises federal agencies and other stakeholders on standards and conformity assessment policy. The Standards Coordination Office is the NIST standardization focal point for federal government, administers the NIST Standards Curricula Development Cooperative Agreement Program, operates the U.S. Inquiry Point for the World Trade Organization’s Technical Barriers to Trade Agreement, is the U.S. Designating Authority for Telecom Mutual Recognition Agreements, and is a key information source for US industry on standards related market access issues.

Gordon has extensive standards experience across a wide range of critical issues including homeland security, safety, health, and protection of the environment. Gordon is an expert on conformity assessment systems design, an advisor to the U.S. Trade Representative on technical barriers to trade and related trade agreements, and has collaborated across the standards community to develop standards based solutions for national priorities throughout his career. Gordon provided direct support in the drafting and negotiation of the Technical Barriers to Trade chapter of the USMCA.

Prior experience includes leading government affairs for the largest U.S. product safety certification and standards development organization, Underwriters Laboratories (UL) in Washington, DC, and Staff Engineer for the medical device and information technology sectors at UL’s Northbrook, IL headquarters.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More